Biocryst Pharmaceuticals (BCRX) Other Non-Current Assets (2011 - 2026)

Biocryst Pharmaceuticals' Other Non-Current Assets history runs 16 years deep, the most recent figure standing at $19.7 million for Q1 2026.

• Quarterly Other Non-Current Assets rose 306.12% year-over-year to $19.7 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $19.7 million (up 306.12% YoY) and the FY2025 annual result came in at $5.7 million, up 9.99% from the prior year.
• Other Non-Current Assets was $19.7 million for Q1 2026 at Biocryst Pharmaceuticals, up from $5.7 million in the prior quarter.
• Across five years, Other Non-Current Assets topped out at $19.7 million in Q1 2026 and bottomed at $80000.0 in Q4 2023.
• A 5-year average of $8.1 million and a median of $6.9 million in 2023 frame the typical range for Other Non-Current Assets.
• Annual changes were most pronounced in 2023 — Other Non-Current Assets slumped 98.82% — and 2024, when it surged 6346.25%.
• Biocryst Pharmaceuticals' Other Non-Current Assets stood at $6.8 million in 2022, then slumped by 98.82% to $80000.0 in 2023, then surged by 6346.25% to $5.2 million in 2024, then climbed by 9.99% to $5.7 million in 2025, then jumped by 247.27% to $19.7 million in 2026.
• Business Quant data shows BCRX's Other Non-Current Assets at $19.7 million in Q1 2026, $5.7 million in Q4 2025, and $4.4 million in Q3 2025.